News
VRCA
5.76
-4.56%
-0.28
Verrica Pharma CEO Jayson Rieger to present at Jefferies Global Healthcare Conference
PUBT · 1d ago
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Barchart · 1d ago
Verrica Pharmaceuticals Coverage Assumed by HC Wainwright & Co. at Buy
Dow Jones · 3d ago
Verrica Pharmaceuticals Price Target Announced at $12.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Assumes Verrica Pharmaceuticals at Buy, Announces Price Target of $12
Benzinga · 3d ago
Verrica Pharmaceuticals assumed with a Buy at H.C. Wainwright
TipRanks · 3d ago
VERRICA PHARMACEUTICALS INC <VRCA.O>: H.C. WAINWRIGHT ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $12
Reuters · 3d ago
U.S. RESEARCH ROUNDUP-Apollo, Phillips 66, Valero Energy
Reuters · 3d ago
Weekly Report: what happened at VRCA last week (0518-0522)?
Weekly Report · 4d ago
Lytix Biopharma Q1 net loss widens to NOK 25.95 million
PUBT · 05/21 05:07
Weekly Report: what happened at VRCA last week (0511-0515)?
Weekly Report · 05/18 09:25
Verrica Pharmaceuticals Earnings Call Highlights Growth, Strain
TipRanks · 05/14 00:29
Verrica CEO presents at H.C. Wainwright BioConnect Investor Conference at NASDAQ
PUBT · 05/13 12:03
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sionna Therapeutics, Inc. (SION), Verrica Pharmaceuticals (VRCA) and Arvinas Holding Company (ARVN)
TipRanks · 05/13 11:30
Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call
Benzinga · 05/13 09:16
Analysts Offer Insights on Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Verrica Pharmaceuticals (VRCA) and Kura Oncology (KURA)
TipRanks · 05/13 02:40
Verrica targets COVE-3 initiation by mid-2026 as Q1 dispensed YCANTH units rise 12.1% sequentially
Seeking Alpha · 05/13 01:42
Verrica Pharmaceuticals reports Q1 adjusted EPS (41c), consensus (59c)
TipRanks · 05/12 21:57
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 05/12 21:15
Verrica Pharmaceuticals Q1 revenue rises on YCANTH demand
Reuters · 05/12 20:12
More
Webull provides a variety of real-time VRCA stock news. You can receive the latest news about Verrica Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About VRCA
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).